UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported) December 17, 2001 Commission File Number 001-10304 AMEXDRUG CORPORATION -------------------- (Exact Name of Registrant as Specified in its Charter) Nevada 95-2251025 ------ ---------- (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 396 South Doheny Drive, Suite 326 --------------------------------- Beverly Hills, California 90211 ------------------------------- (Address of principal executive offices) (Zip Code) (310) 855-0475 -------------- (Registrant's Executive Office Telephone Number) 1 Item 8. Change in Fiscal Year On December 21, 2001, Amexdrug Corporation, a California corporation ("Amex CA") filed a Current Report on Form 8-K disclosing that for purposes of redomiciling the Company from California to Nevada, Amex CA entered into a Merger Agreement with Amexdrug Corporation, a Nevada corporation, ("Amex NV"), with Amex NV being the surviving corporation. The Company inadvertently failed to disclose that the fiscal year end of the surviving entity is December 31. Accordingly, at the time of the merger, the Company changed its fiscal year end from June 30 to December 31. The first report affected by this change will be the 10- KSB report for the year ended December 31, 2001, which the Company will file within 90 days of December 31, 2001. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. AMEXDRUG CORPORATION Date: February 21, 2001 By /s/ Jack Amin --------------------------------------------- Jack Amin, President, Chief Financial Officer 2